Rowan University and Sentrimed, a clinical-stage biopharmaceutical company focused on developing safer, orally dosed oncology therapies, today announced results from a National Cancer Institute (NCI) ...

Clinical trial updates in cancer care include a remote study in small cell lung cancer and new findings in ovarian, solid ...

Q2 2025 Management View CEO Richard A. Miller stated the company's main focus remains the development of soquelitinib for atopic dermatitis, highlighting "an oral medication featuring a novel ...

Q1 2026 Management View CEO Shawn K. Singh highlighted progress on the company's late-stage neuroscience pipeline, emphasizing the advancement of intranasal fasedienol through Phase III development ...

Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Thursday, August 7, 2025. Lisata Therapeutics ...

Relay Therapeutics beat analyst estimates for both GAAP revenue and earnings per share in Q2 2025. The company reported continued clinical advancement of its lead asset RLY-2608, with new positive ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ETCompany ParticipantsArnon Rosenthal - Co-Founder, CEO ...

Corvus Pharmaceuticals reported a net loss per share of $(0.10) for Q2 2025, a smaller loss than the analyst estimate of $(0.13). Research and development expenses rose sharply to $7.9 million, ...

Cardiol Therapeutics (TSX: CRDL) (NYSE: CRDL) has released topline results from their phase two ARCHER trial targeting ...